• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Ivantis

Alcon closes Ivantis acquisition

January 10, 2022 By Sean Whooley

Alcon (NYSE:ALC) announced today that it completed its $475 million acquisition of glaucoma surgery device maker Ivantis. Geneva, Switzerland-based Alcon initially announced the acquisition of Ivantis, which develops the Hydrus Microstent minimally invasive glaucoma surgery (MIGS) device, in November 2021. Get the full story at our sister site, Medical Tubing & Extrusion.

Filed Under: Business/Financial News, Featured, Implants, Mergers & Acquisitions, Optical/Ophthalmic Tagged With: Alcon, Ivantis

Alcon to acquire Ivantis for $475M

November 8, 2021 By Sean Whooley

Alcon (NYSE:ALC) announced today that it intends to acquire glaucoma surgery device maker Ivantis for $475 million upfront. Geneva, Switzerland-based Alcon aims to bolster its portfolio across cataract, refractive, retina and glaucoma offerings by acquiring Ivantis and its novel Hydrus Microstent for minimally invasive glaucoma surgery (MIGS). Ivantis designed the Hydrus Microstent to lower intraocular […]

Filed Under: Business/Financial News, Featured, Implants, Mergers & Acquisitions, Optical/Ophthalmic, Surgical, Wall Street Beat Tagged With: Alcon, Ivantis

Ivantis to pay $60M in patent litigation settlement with Glaukos

September 15, 2021 By Sean Whooley

Glaukos (NYSE:GKOS) announced today that it entered into a settlement with Ivantis to terminate a three-year-old patent infringement lawsuit. San Clemente, California-based Glaukos’ patent infringement lawsuit, initiated on April 14, 2018, in the U.S. District Court for the Central District of California, Southern Division, concerned Ivantis’ Hydrus Microstent for reducing eye pressure in glaucoma patients. Get the full […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Stents Tagged With: Glaukos, Ivantis

Glaukos touts 5-year study of glaucoma stents

April 15, 2019 By Nancy Crotti

Glaukos  (NYSE:GKOS) said today that a study of its iStent trabecular micro-bypass stents reduced eye pressure in glaucoma patients five years after implant. The same study showed that significantly fewer iStent patients needed add-on medications after five years, the company said. The study showed that newly diagnosed, primary open-angle glaucoma (POAG) patients who received two […]

Filed Under: Clinical Trials, Featured, Implants, News Well, Optical/Ophthalmic, Vision Tagged With: Glaukos, Ivantis

Ivantis touts 2-year Hydrus, Glaukos iStent head-to-head study results

March 14, 2019 By Fink Densford

Ivantis today released two-year results from a study comparing its Hydrus Microstent to Glaukos‘ (NYSE:GKOS) iStent trabecular micro-bypass stents, touting reductions in medication use and no reoperations for patients in the Hydrus arm. The Irvine, Calif.-based company said that it is presenting results from the Compare trial today at the American Glaucoma Society’s annual meeting in […]

Filed Under: Clinical Trials, Optical/Ophthalmic Tagged With: Glaukos, Ivantis

New eye health companies gain funders’ focus

October 17, 2018 By Nancy Crotti

Startups pioneering less-invasive technologies to treat common eye diseases are changing the outlook for both patients and the industry. A new study by CB Insights revealed that investors have been pouring money into smaller companies in 2017 and 2018, with some FDA approvals to begin marketing their technologies and treatments. These firms are eyeing conditions […]

Filed Under: Featured, Funding Roundup, Optical/Ophthalmic, Vision Tagged With: AcuFocus Inc., Alphabet (Google), azura, CB Insights, Ivantis, lensgen, rxsight, tearfilminnovations

FDA approves Ivantis’ Hydrus microstent

August 13, 2018 By Fink Densford

Ivantis said today it won FDA approval for its Hydrus microstent designed to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The Hydrus microstent is designed for minimally invasive microsurgical procedures to reduce eye pressure in patients with glaucoma. The device is multi-modal, the company said, by creating a large […]

Filed Under: Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: Ivantis

Ivantis touts 1-year head-to-head Hydrus, Glaukos iStent study data

April 16, 2018 By Fink Densford

Ivantis today released one-year results from the study of its Hydrus Microstent comparing it to Glaukos‘ (NYSE:GKOS) iStent trabecular micro-bypass stents, touting the Hydrus’ ability to reduce reliance on medication and intraocular pressure. Results from the trial were presented at the American Society of Cataract and Refractive Surgery annual meeting in Washington D.C. by Dr. David […]

Filed Under: Clinical Trials, Optical/Ophthalmic Tagged With: Glaukos, Ivantis

Ivantis launches 2nd IDE study of Hydrus microstent

April 25, 2017 By Fink Densford

Ivantis said today it won approval from the FDA to initiate a 2nd investigational device exemption trial of its Hydrus microstent, testing the device in patients with advanced glaucoma who are undergoing stand-alone glaucoma surgery without combined cataract surgery. The Hydrus microstent is designed for minimally invasive microsurgical procedures to reduce eye pressure in patients with […]

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Optical/Ophthalmic Tagged With: Ivantis

Ivantis raises $25m in Series C to support Hydrus microstent

January 9, 2017 By Fink Densford

Ivantis said today it raised $25 million in a Series C round of financing to support its Hydrus microstent device designed for treating glaucoma. The round was led by newly invested RA Capital Management and joined by new investor Mérieux Développement and existing investors. Money raised will extend Irvine, Calif.-based Ivantis’ runway into 2020 and […]

Filed Under: Business/Financial News, Optical/Ophthalmic Tagged With: Ivantis

Silicon Valley Bank’s Ben Johnson talks early-stage medtech investment slump | Medtech funding for the week of September 22, 2014

September 26, 2014 By MassDevice Leave a Comment

What's behind the slump in early-stage medtech investment?

September 24, 2014 by Brad Perriello

Filed Under: Funding Roundup, News Well Tagged With: iHealth, Ivantis, Minerva Surgical Inc., Palmaz Scientific, Silicon Valley Bank

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS